citizen

[url="http://unisci.com/stories/20001/0121001.htm"]http://unisci.com/stories/20001/0121001.htm[/url]

tetrathiomolybdate is a copper lowering drug that in my opinion has great promise. Lowering copper levels to 20% of normal interferes with the advancement of the cancer. The University of Michigan is the only place where is is being tested with a Dr. Brewer in charge. I believe they are in second level trials. Please call them and ask questions to your satisfaction. There are a few mentions on web pages that will give you more information. I've talked to the people at the U of M and they told me about a person at a drug company in Wisconsin that will make it available if a doctor is willing to monitor the levels of copper in your system. The following is from the JAMA site:


Copper and Cancer

Rebecca Voelker



Depriving malignant tumors of their copper supply may be a potent antiangiogenesis strategy for stabilizing patients with advanced cancer.

In last month's Clinical Cancer Research, investigators at the University of Michigan Medical School described a surprise finding from a clinical trial designed to determine how well tetrathiomolybdate (TM), an inexpensive compound, could lower copper levels in patients with cancer. In five of six patients kept at 20% of normal copper levels for more than 90 days, existing tumors did not grow and new tumors did not form for more than 1 year. Another 12 patients could not achieve or maintain the target copper level for 90 days because of disease progression.

Copper reduction appears to be effective in fighting multiple types of cancer. Patients in the study had metastatic cancer of the breast, kidney, colon, lung, skin, pancreas, and other sites. "What began as a scientific hunch now appears to have potential as a simple but effective general antiangiogenesis strategy," said George Brewer, MD, professor of human genetics. A trial of TM in patients with less advanced cancers is being planned.